HCID 71226800, compound → HCID 136627208, compound

Participants

Reaction Steps

The title compound (14.8 mg, 0.031 mmol) was prepared following the general procedure of Example 1 from {4-[5-(4-fluoro-phenyl)-[1,3,4]oxadiazol-2-yl]-piperidin-1-yl}-acetic acid (90 mg, 0.206 mmol, 1 eq) and 2-aminomethyl-3,5,7,8-tetrahydro-pyrano[4,3-d]pyrimidin-4-one (41.1 mg, 0.227 mmol, 1.1 eq). 1H NMR (400 MHz, DMSO-d6) δ ppm 12.38 (br s, 1H) 8.23-8.26 (m, 1H) 8.05 (dd, J=8.84, 5.31 Hz, 2H) 7.43-7.47 (m, 2H) 4.34 (s, 2H) 4.20 (d, J=5.56 Hz, 2H) 4.04-4.11 (m, 1H) 3.80-3.83 (m, 2H) 3.17 (d, J=5.05 Hz, 2H) 3.03-3.11 (m, 1H) 3.01 (s, 2H) 2.93-2.99 (m, 2H) 2.27-2.33 (m, 2H) 2.05-2.10 (m, 2H) 1.85-2.01 (m, 2H). HR-MS (m/z, MH+): 469.2001, 470.2061. HPLC retention time: 2.66 min (Agilent column 3.0×100 mm 3 um C18 column; flow rate of 1.0 mL/min with gradient from 5% to 95% acetonitrile in 10 min, 0.1% FA).

Provenance & Evidence